OBLN - オバロン・セラピュ―ティクス (Obalon Therapeutics Inc.)

OBLNのニュース

   New Comprehensive Report on Obesity Intervention Devices Market 2020-2027| EnteroMedics, Apollo Endosurgery, Cousin Biotech, Aspire Bariatrics, Obalon Therapeutics  2020/11/23 12:44:49 OpenPR
HealthCare Intelligence Markets unravels its new study titled Obesity Intervention Devices Market. Effective exploratory techniques such as qualitative and quantitative analysis have been used to discover accurate data. For an effective business outlook, it studies North America, Latin America, Asia-Pacific,
   The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortfall, Alcon To Delay Dividend Initiation  2020/04/07 11:55:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs April 6.) Forty Seven Inc (NASDAQ: FTSV ) Masimo Corporation (NASDAQ: MASI ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) Down In The Dumps (Biotech stocks that hit 52-week lows April 6) BIOLASE Inc (NASDAQ: BIOL ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Global Cord Blood Corp (NYSE: CO ) ImmuCell Corporation (NASDAQ: ICCC ) IMMURON LTD/S ADR (NASDAQ: IMRN ) Menlo Therapeutics Inc (NASDAQ: MNLO ) (flunked two late-stage studies that evaluated oral serlopitant for treating pruritus associated with prurigo nodularis) Merus NV (NASDAQ: MRUS ) Millendo Therapeutics Inc (NASDAQ: MLND ) (said it is discontinuing development of livoletide as a potential treatment for Prader-Willi syndrome following failed Phase 2b study) Obalon Therapeutics Inc (NASDAQ: OBLN ) Quest Diagnostics Inc (NYSE: DGX ) (said it has performed 550,000 COVID-19 tests) Second Sight Medical Products Inc (NASDAQ: EYES ) Stocks In Focus Sanofi, Regeneron Finalize Previously Announced Praluent Restructuring Sanofi SA (NASDAQ: SNY ) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) announced they have finalized the planned restructuring related to cholesterol drug Praluent.
   Obalon +8.6% on new stock purchase agreement  2020/02/07 23:27:06 Seeking Alpha
Obalon Therapeutics (NASDAQ:OBLN) is up 8.6% postmarket after entering into a new stock purchase agreement and registration rights agreement with Lincoln P
   Is OBALON THERPTCS (OBLN) Stock Outpacing Its Medical Peers This Year?  2020/01/24 16:30:10 Zacks Investment Research
Is (OBLN) Outperforming Other Medical Stocks This Year?
   Obalon Therapeutics Inc (NASDAQ:OBLN) CEO Buys $107,900.00 in Stock  2019/11/17 12:38:32 Modern Readers
Obalon Therapeutics Inc (NASDAQ:OBLN) CEO William J. Plovanic acquired 65,000 shares of the stock in a transaction dated Tuesday, November 12th. The shares were purchased at an average cost of $1.66 per share, with a total value of $107,900.00. Following the completion of the purchase, the chief executive officer now owns 106,806 shares of the […]
   The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortfall, Alcon To Delay Dividend Initiation  2020/04/07 11:55:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs April 6.) Forty Seven Inc (NASDAQ: FTSV ) Masimo Corporation (NASDAQ: MASI ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) Down In The Dumps (Biotech stocks that hit 52-week lows April 6) BIOLASE Inc (NASDAQ: BIOL ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Global Cord Blood Corp (NYSE: CO ) ImmuCell Corporation (NASDAQ: ICCC ) IMMURON LTD/S ADR (NASDAQ: IMRN ) Menlo Therapeutics Inc (NASDAQ: MNLO ) (flunked two late-stage studies that evaluated oral serlopitant for treating pruritus associated with prurigo nodularis) Merus NV (NASDAQ: MRUS ) Millendo Therapeutics Inc (NASDAQ: MLND ) (said it is discontinuing development of livoletide as a potential treatment for Prader-Willi syndrome following failed Phase 2b study) Obalon Therapeutics Inc (NASDAQ: OBLN ) Quest Diagnostics Inc (NYSE: DGX ) (said it has performed 550,000 COVID-19 tests) Second Sight Medical Products Inc (NASDAQ: EYES ) Stocks In Focus Sanofi, Regeneron Finalize Previously Announced Praluent Restructuring Sanofi SA (NASDAQ: SNY ) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) announced they have finalized the planned restructuring related to cholesterol drug Praluent.
   Obalon +8.6% on new stock purchase agreement  2020/02/07 23:27:06 Seeking Alpha
Obalon Therapeutics (NASDAQ:OBLN) is up 8.6% postmarket after entering into a new stock purchase agreement and registration rights agreement with Lincoln P
   Is OBALON THERPTCS (OBLN) Stock Outpacing Its Medical Peers This Year?  2020/01/24 16:30:10 Zacks Investment Research
Is (OBLN) Outperforming Other Medical Stocks This Year?
   Obalon Therapeutics Inc (NASDAQ:OBLN) CEO Buys $107,900.00 in Stock  2019/11/17 12:38:32 Modern Readers
Obalon Therapeutics Inc (NASDAQ:OBLN) CEO William J. Plovanic acquired 65,000 shares of the stock in a transaction dated Tuesday, November 12th. The shares were purchased at an average cost of $1.66 per share, with a total value of $107,900.00. Following the completion of the purchase, the chief executive officer now owns 106,806 shares of the […]
   OBALON THERPTCS (OBLN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release  2019/11/01 14:30:29 Zacks Investment Research
OBALON THERPTCS (OBLN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortfall, Alcon To Delay Dividend Initiation  2020/04/07 11:55:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs April 6.) Forty Seven Inc (NASDAQ: FTSV ) Masimo Corporation (NASDAQ: MASI ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) Down In The Dumps (Biotech stocks that hit 52-week lows April 6) BIOLASE Inc (NASDAQ: BIOL ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Global Cord Blood Corp (NYSE: CO ) ImmuCell Corporation (NASDAQ: ICCC ) IMMURON LTD/S ADR (NASDAQ: IMRN ) Menlo Therapeutics Inc (NASDAQ: MNLO ) (flunked two late-stage studies that evaluated oral serlopitant for treating pruritus associated with prurigo nodularis) Merus NV (NASDAQ: MRUS ) Millendo Therapeutics Inc (NASDAQ: MLND ) (said it is discontinuing development of livoletide as a potential treatment for Prader-Willi syndrome following failed Phase 2b study) Obalon Therapeutics Inc (NASDAQ: OBLN ) Quest Diagnostics Inc (NYSE: DGX ) (said it has performed 550,000 COVID-19 tests) Second Sight Medical Products Inc (NASDAQ: EYES ) Stocks In Focus Sanofi, Regeneron Finalize Previously Announced Praluent Restructuring Sanofi SA (NASDAQ: SNY ) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) announced they have finalized the planned restructuring related to cholesterol drug Praluent.
   Obalon +8.6% on new stock purchase agreement  2020/02/07 23:27:06 Seeking Alpha
Obalon Therapeutics (NASDAQ:OBLN) is up 8.6% postmarket after entering into a new stock purchase agreement and registration rights agreement with Lincoln P
   Is OBALON THERPTCS (OBLN) Stock Outpacing Its Medical Peers This Year?  2020/01/24 16:30:10 Zacks Investment Research
Is (OBLN) Outperforming Other Medical Stocks This Year?
   Obalon Therapeutics Inc (NASDAQ:OBLN) CEO Buys $107,900.00 in Stock  2019/11/17 12:38:32 Modern Readers
Obalon Therapeutics Inc (NASDAQ:OBLN) CEO William J. Plovanic acquired 65,000 shares of the stock in a transaction dated Tuesday, November 12th. The shares were purchased at an average cost of $1.66 per share, with a total value of $107,900.00. Following the completion of the purchase, the chief executive officer now owns 106,806 shares of the […]
   OBALON THERPTCS (OBLN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release  2019/11/01 14:30:29 Zacks Investment Research
OBALON THERPTCS (OBLN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

calendar